Wave Life Sciences
WVEWave Life Sciences is a clinical-stage biotechnology company specializing in the development of RNA-based medicines through its proprietary PRISM platform.
Earnings
Next report
Jul 30, 2026 (Tomorrow)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Wave Life Sciences is a clinical-stage biotechnology company specializing in the development of RNA-based medicines through its proprietary PRISM platform. The company utilizes multiple modalities, including RNA interference, RNA editing, and antisense splicing, to target the transcriptome and treat both rare and common genetic disorders. Their approach focuses on optimizing oligonucleotide chemistry to enhance drug potency and durability without the need for complex delivery vehicles.
A pioneer in stereopure oligonucleotide chemistry and RNA editing, holding a leading position in endogenous ADAR-mediated RNA correction.
Questions, answered.
- What is Wave Life Sciences's market cap?
- Wave Life Sciences (WVE) has a market capitalization of $1.1B and trades on NASDAQ.
- What is Wave Life Sciences's revenue and profitability?
- Wave Life Sciences generated $75.8M in trailing twelve-month revenue with a net loss of $183.6M, representing a net margin of -66.5%, with free cash flow of -$185.0M. These figures are based on the Q1 2026 filing.
- Who are Wave Life Sciences's competitors?
- Wave Life Sciences's key competitors include Eli Lilly, Sarepta Therapeutics, Madrigal Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does Wave Life Sciences partner with?
- Wave Life Sciences's notable partners include Novo Nordisk, Eli Lilly, Sarepta Therapeutics, and others.
- Where is Wave Life Sciences headquartered?
- Wave Life Sciences is headquartered in Singapore and employs approximately 268 people. It has been publicly traded since 2015.
